Healthcare

For an S&P/ASX 200 company whose growth is driven by selling cloud-based software into large US health systems, that combination of softwareLeadershipand board experience is a logical and timely fit.

Proteomics International develops proprietary blood-based diagnostic tests using proteomic biomarker analysis. The Promarker® portfolio currently consists of three products: Promarker®D, which assesses risk for diabetic kidney disease up to four years before clinical symptoms appear; Promarker®Eso, which assists in ruling out oesophageal cancer in …

Hydration Pharmaceuticals operates in the hydration products sector, developing andMarketingproducts designed to support hydration management. The company is based in San Diego, California — a hub for life sciences and pharmaceutical companies — and is focused on the US market.

Adheris Health provides pharma marketing and patient engagement technology services to pharmaceutical companies in the United States. The company's primary offering, THRiV, is a digital engagement platform that enables pharmaceutical brands to run targeted, data-driven patient engagement programs. Digital engagement programs are structured campaigns …

Chimeric Therapeutics holds exclusive licences across three intellectual property assets. The Chlorotoxin (CLTX) CAR-T technology was licensed from City of Hope in Los Angeles and targeted the treatment of brain tumours. The CDH-17 CAR-T technology was licensed from the University of Pennsylvania and was …

Cynata's proprietary Cymerus™ platform uses a single donor iPSC source to produce MSC therapeutics at scale. The company has advanced two primary clinical programs: CYP-001, targeting acute graft versus host disease (aGvHD), and CYP-004, targeting osteoarthritis of the knee. A third program, CYP-006TK, involves …

Ceryvyn Therapeutics' lead asset is CYV-101, a first-in-class fusion protein designed to selectively bind and neutralise VEGF-C and VEGF-D — key signalling proteins involved in pathological lymphangiogenesis. The company's scientific hypothesis is that by targeting this biological pathway, CYV-101 may offer a differentiated therapeutic …